|Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer.|
|PMID: 23147449 Owner: NLM Status: MEDLINE|
|OBJECTIVES: The inflammation-based Glasgow Prognostic Score (GPS) is associated with outcome in a variety of cancers. This study investigated whether a modified GPS (mGPS) could predict survival in patients undergoing multimodality therapy for advanced colorectal cancer (CRC).
METHODS: We enrolled 245 patients with advanced CRC who received chemotherapy. The mGPS was recorded prior to first-line chemotherapy and to cytoreductive therapy including secondary surgery and/or radiofrequency ablation. The prognostic significance of the mGPS was analyzed using Kaplan-Meier, univariate, and multivariate analyses.
RESULTS: In patients who received chemotherapy alone (n = 163), the mGPS prior to chemotherapy was an independent prognostic indicator of survival [odds ratio (OR) 1.858; 95% confidence interval (CI) 1.213-2.846; p = 0.0044]. In patients who also underwent cytoreductive therapy (n = 82), the mGPS decreased after chemotherapy in 22 patients (27%) and increased in 5 (6%). In these patients, the mGPS prior to cytoreductive therapy was an independent prognostic indicator of survival (OR 3.412; 95% CI 1.198-9.720; p = 0.0216), but the mGPS prior to chemotherapy was not.
CONCLUSIONS: The mGPS is an independent prognostic indicator of survival in patients undergoing multimodality therapy for advanced CRC, if recorded at a relevant time point.
|Yasuhiro Inoue; Takashi Iwata; Yoshinaga Okugawa; Aya Kawamoto; Junichiro Hiro; Yuji Toiyama; Koji Tanaka; Keiichi Uchida; Yasuhiko Mohri; Chikao Miki; Masato Kusunoki|
Related Documents :
|24596519 - Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated rad...
11569889 - Randomized open-label trial of dolasetron for the control of nausea and vomiting associ...
7651559 - Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
25118489 - Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemother...
23852309 - Bevacizumab plus chemotherapy continued beyond first progression in patients with metas...
17085949 - Relationships among speech perception, self-rated tinnitus loudness and disability in t...
9272139 - High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and pe...
14675349 - Surgical treatment of lymph node metastases in stage ib cervical cancer: the laterally ...
11990229 - Forced expiratory time and bronchial hyperresponsiveness to methacholine.
|Type: Journal Article Date: 2012-11-09|
|Title: Oncology Volume: 84 ISSN: 1423-0232 ISO Abbreviation: Oncology Publication Date: 2013|
|Created Date: 2012-12-21 Completed Date: 2013-02-21 Revised Date: 2014-03-06|
Medline Journal Info:
|Nlm Unique ID: 0135054 Medline TA: Oncology Country: Switzerland|
|Languages: eng Pagination: 100-7 Citation Subset: IM|
|Copyright © 2012 S. Karger AG, Basel.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
C-Reactive Protein / metabolism
CA-19-9 Antigen / metabolism
Carcinoembryonic Antigen / metabolism
Colorectal Neoplasms / complications, mortality*, therapy
Combined Modality Therapy / adverse effects*
Inflammation / diagnosis, etiology*, metabolism
Serum Albumin / metabolism
Tumor Markers, Biological / analysis*
|0/CA-19-9 Antigen; 0/Carcinoembryonic Antigen; 0/Serum Albumin; 0/Tumor Markers, Biological; 9007-41-4/C-Reactive Protein|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development of qualitative and quantitative analysis methods in pharmaceutical application with new ...
Next Document: Arrhythmogenic Right Ventricular Cardiomyopathy: The Challenge of Genetic Interpretation in Clinical...